Compare Canadian Natural Resources Ltd. (CNQ) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canadian Natural Resources Ltd. vs Moderna, Inc. — how do they compare? Canadian Natural Resources Ltd. trades at $47.64 (market cap $98.11B), while Moderna, Inc. trades at $60.51 (market cap $24.18B). The key difference: Canadian Natural Resources Ltd. is far larger — about 4.1× Moderna, Inc.'s market cap, and Canadian Natural Resources Ltd. pays a 3.73% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| CNQ | MRNA | |
|---|---|---|
Market Cap | $98.11B | $24.18B |
Sector | Energy | Health |
52-Week High | $50.55 | $81.80 |
52-Week Low | $29.31 | $22.36 |
Enterprise Value | $108.54B | $20.33B |
Dividend Yield | 3.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canadian Natural Resources (CNQ) trades at $47.65, up 0.85% with strong technical momentum. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $1.53 versus $1.43 expected, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 11.82 and EV/EBITDA of 6.35, while profitability metrics impress with 26.69% ROE and 22.87% net margin. Recent news highlights record production and dividend consistency.
CNQ presents a compelling investment case with strong operational performance, attractive valuation, and shareholder returns through dividends. The primary risks include oil price volatility and execution challenges in capital projects. Analyst consensus remains strongly bullish with 27 buy ratings and no sell recommendations, supporting upside potential from current levels.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
